REG - Physiomics PLC - Cancellation of General Meeting

PhysiomicsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260320:nRST3873Xa&default-theme=true

RNS Number : 3873X  Physiomics PLC  20 March 2026

Unless otherwise defined herein, the capitalised terms used in this
announcement have the same meaning as those used in the Company's
announcements released on 10 March 2026.

 

20 March 2026

 

Physiomics Plc

("Physiomics" or the "Company")

 

Cancellation of General Meeting

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, announces that the General Meeting previously
scheduled to convene at 10:00 a.m. on Tuesday 7 April 2026 at the Copthorne
Hotel Slough-Windsor, Cippenham Lane, Slough, Berkshire, SL1 2YE will no
longer take place.

 

Reason for cancellation

 

The Company's Board has concluded that it is unnecessary to proceed with the
General Meeting on 7 April 2026 for the following reasons:

 

·    on 10 March 2026, the Company announced a proposed placing and retail
offer (the "Placing") to raise up to approximately £500,000 at a placing
price of 0.3 pence per share, conditional upon the passing of certain
resolutions at the General Meeting scheduled for 7 April 2026;

 

·    following a review by the Board of the terms and structure of that
placing the Company cancelled the Placing and completed (subject to Admission
only) a revised placing and retail offer at an increased placing price of 0.4
pence per share (the "Revised Placing"), as announced on 17 March 2026; and

 

·    the resolutions that were to be proposed at the General Meeting on 7
April 2026 are no longer appropriate, as they were drafted to reflect the
terms of the original Placing at 0.3 pence per share.

 

The Board believes that the Revised Placing is in the best interests of the
Company and its shareholders as a whole.

 

Existing proxy appointments

 

Any proxy appointments that you have already submitted in respect of the
General Meeting scheduled for 7 April 2026 will not be valid.

 

No action required

 

You do not need to take any action at this stage.

 

You should not attend at the Copthorne Hotel Slough-Windsor on 7 April 2026,
as no meeting will be held on that date.

 

 

Further Information

 

If you have any questions about this cancellation or about your shareholding,
please contact the Customer Support Centre of MUFG Corporate Markets, the
Company's Registrars, on 0371 664 0300 or by email at
shareholderenquiries@cm.mpms.mufg.com. Calls are charged at the standard
geographic rate and will vary by provider. Calls outside the United Kingdom
will be charged at the applicable international rate. Lines are open between
09:00 - 17:30, Monday to Friday excluding public holidays in England and
Wales.

 

We thank you for your continued support of the Company.

 

 

 Physiomics plc                 +44 (0) 1235 841575
 Dr Peter Sargent, CEO

 Hybridan LLP (Broker)          +44 (0) 203 764 2341
 Claire Louise Noyce

 Strand Hanson Limited (NOMAD)  +44 (0) 20 7409 3494

 James Dance, James Bellman

 

Further information on the Company can be found on its website at
www.physiomics.co.uk

 

The Company's LEI is 213800A71DSZ6ABMTQ91.

 

 Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDKLFFQXLXBBV



            Copyright 2019 Regulatory News Service, all rights reserved